Real-Life Data in the Treatment of Neovascular Age-Related Macular Degeneration: Results from the Imaculaweb Registry Evaluated in a Single Italian Medical Retina Center

Nicolò, Massimo; Morlacchi, Alessia; Cappelli, Francesca; Desideri, Lorenzo Ferro; Colombo, Virginia; Musetti, Donatella; Musolino, Maria; Saccheggiani, Michela; Bonetto, Monica; Traverso, Carlo Enrico

doi:10.1159/000507711

Cited by 18 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, relevant statistical studies have found that patient compliance is decreasing every year. Such as in one study, it was reported that the injection numbers were 5.2, 2.6, and 2.3 at the 1-, 2-, and 3-year follow-ups, respectively ( 19 ), affecting treatment outcomes. Therefore, the development of new treatment directly acts on HMECs options is of particular importance.…”

Section: Introductionmentioning

confidence: 96%

Regulator of G-protein signaling 1 promotes choroidal neovascularization in age-related macular degeneration

Zhang¹,

Zhang²,

Guo³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

Background: Age-related macular degeneration (AMD) is the leading cause of blindness, and is associated with oxidative stress and the development of new blood vessels. At present, the main clinical treatment for AMD includes intraocular injection of vascular endothelial growth factor (VEGF). However, treatment includes repeated injections with significant side-effects. Therefore, new treatment options are required. The aim of the present study was to discover the new treatment target of AMD from the gene level. Methods: The Gene Expression Omnibus (GEO) database was used to analyze the differential gene expression in AMD, and the regulator of G-protein signaling 1 (RGS1) was obtained by bioassay. Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to detect the expression levels of RGS1, VEGF, and other related molecules in human microvascular endothelial cells (HMECs) under different conditions. Cell viability, apoptosis, and proliferation of HMECs were measured by Cell Counting Kit-8 proliferation assay. Immunofluorescence and immunohistochemistry detected the interaction between RGS1, platelet endothelial cell adhesion molecule-1, and VEGF. Results: RGS1 was found to closely associated with the proliferation of vascular endothelial cells, and therefore, with angiogenesis. The expression of RGS1, VEGF, and platelet endothelial cell adhesion molecule-1 was upregulated in laser model mice and hypoxia model HMECs. Knockout of RGS1 inhibits the expression of VEGF and HMEC proliferation, thereby inhibiting AMD angiogenesis. Conclusions: Our results support the use of RGS1 as a new potential target for the future treatment of AMD.

show abstract

Section: Introductionmentioning

confidence: 96%

Regulator of G-protein signaling 1 promotes choroidal neovascularization in age-related macular degeneration

Zhang¹,

Zhang²,

Guo³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…The practice of intravitreal injection (IVT) with anti-vascular endothelial growth factor (VEGF) has significantly impacted the outcomes of exudative macular diseases in recent years and nowadays represents the most frequently performed ocular procedure [1][2][3][4]; moreover, the frequency of this procedure is growing worldwide and, in parallel, the risk of procedure-related complications [5]. Among them, endophthalmitis, the most fearful ocular complication, has a reported incidence ranging from 0.019% to 0.083% [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Efficacy of a New Commercial Ocular Spray Containing Oftasecur Citrus Extract for Reducing Microbial Load in the Conjunctiva of Patients Receiving Intravitreal Injections

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: The control of conjunctival microbial load is crucial for patients receiving intravitreal injections (IVTs) in order to reduce the risk of endophthalmitis. The purpose of this work was to assess the antimicrobial activity of a new commercial ocular spray containing Biosecur citrus extract (Oftasecur Ò , Off Health, Florence, Italy). Methods: This prospective cross-sectional pilot study included patients receiving IVTs who were instructed to apply Oftasecur spray onto the eye to be injected four times daily starting 4 days before surgery. The contralateral eye was considered the control. A conjunctival swab for microbiological analysis was performed in both eyes before starting study treatment and at the time of the injection. The Brief Ocular Discomfort Inventory (BODI) questionnaire was administered to patients based on an 11-point scale (0 for no discomfort and 10 for maximum discomfort). Results: Thirty patients (15 male, 15 female; mean age 64.7 ± 11.6 [standard deviation, SD] years) were included. Before starting treatment, 53.3% of the total eyes tested positive during

show abstract

“…In addition to intensive glycemic control, the management of DME requires multidisciplinary care, including intravitreal anti-vascular endothelial growth factor (VEGF) drugs, intravitreal corticosteroids, laser photocoagulation, and vitrectomy [3,4]. Currently, intravitreal anti-VEGF drugs are mostly regarded as first-line therapy [5][6][7]. However, a significant number of DME patients do not respond to anti-VEGF drugs, and non-VEGF mediators are urgently needed for these patients [8].…”

Section: Introductionmentioning

confidence: 99%

Intravitreal corticosteroids for diabetic macular edema: a network meta-analysis of randomized controlled trials

2021

View full text Add to dashboard Cite

Background To evaluate the efficacy and safety of different intravitreal corticosteroids for treating diabetic macular edema (DME). Methods Four databases were systematically searched for randomized controlled trials comparing different intravitreal corticosteroids for treating DME. The primary outcome was the change in best-corrected visual acuity (BCVA) within 6 months after the first injection (short-term BCVA). Secondary outcomes were the change in BCVA over 1 year (long-term BCVA) and changes in central macular thickness (CMT) and intraocular pressure (IOP) within 6 months after the first injection. Network meta-analysis was performed to aggregate the results from the individual studies. Results Nineteen trials involving 2839 eyes were included. Intravitreal triamcinolone acetonide (TA) injections (≥ 8 mg and 4–8 mg), fluocinolone acetonide (FA) implants (0.5 µg/day) and dexamethasone (DEX) implants (700 µg) improved short-term BCVA (mean changes in logMAR [95% confidence interval] − 0.27 [− 0.40, − 0.15]; − 0.12 [− 0.18, − 0.06]; − 0.10 [− 0.21, − 0.01]; and − 0.06 [− 0.11, − 0.01]). Intravitreal TA injections (4 mg, multiple times), FA implants (0.5 µg/day and 0.2 µg/day), and DEX implants (350 µg) improved long-term BCVA (mean changes in logMAR [95% confidence interval] − 0.11 [− 0.21, − 0.02]; − 0.09 [− 0.15, − 0.03]; − 0.09 [− 0.14, − 0.02]; and − 0.04 [− 0.07, − 0.01]). All intravitreal corticosteroids reduced CMT, and different dosages of TA did not show significant differences in increasing IOP. Conclusions Intravitreal corticosteroids effectively improved BCVA in DME patients, with higher dosages showing greater efficacies. TA was not inferior to FA or DEX and may be considered a low-cost alternative choice for DME patients. The long-term efficacy and safety of different corticosteroids deserve further investigation. Trial registration Prospectively registered: PROSPERO, CRD42020219870

show abstract

Real-Life Data in the Treatment of Neovascular Age-Related Macular Degeneration: Results from the Imaculaweb Registry Evaluated in a Single Italian Medical Retina Center

Cited by 18 publications

References 32 publications

Regulator of G-protein signaling 1 promotes choroidal neovascularization in age-related macular degeneration

Regulator of G-protein signaling 1 promotes choroidal neovascularization in age-related macular degeneration

Efficacy of a New Commercial Ocular Spray Containing Oftasecur Citrus Extract for Reducing Microbial Load in the Conjunctiva of Patients Receiving Intravitreal Injections

Intravitreal corticosteroids for diabetic macular edema: a network meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About